Publikationen in Zusammenarbeit mit Forschern von Radboud University Nijmegen Medical Centre (10)

2023

  1. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    European Urology

  2. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    European Journal of Cancer

2022

  1. Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib

    Cancers, Vol. 14, Núm. 12

  2. Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer

    Kidney Cancer, Vol. 6, Núm. 3, pp. 169-178

  3. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

    Clinical Cancer Research, Vol. 28, Núm. 10, pp. 2050-2060

2020

  1. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

    European Urology

  2. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees

    European Urology, Vol. 77, Núm. 2, pp. 223-250

2019

  1. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

    Annals of Oncology, Vol. 30, Núm. 11, pp. 1697-1727

2018

  1. A genetic polymorphism in ctla-4 is associated with overall survival in sunitinib-treated patients with clear cell metastatic renal cell carcinoma

    Clinical Cancer Research, Vol. 24, Núm. 10, pp. 2350-2356

2017

  1. Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer—GEnetic- and tumor-related biomarkers for response and toxicity

    Urologic Oncology: Seminars and Original Investigations, Vol. 35, Núm. 8, pp. 529.e9-529.e16